帕吉昔单抗

化合物

帕吉昔单抗INN:Pagibaximab)是一种嵌合单克隆抗体,用于预防低出生体重婴儿葡萄球菌败血症。截至2010年3月,该药物尚在进行II/III期临床试验[1][2]

帕吉昔单抗
单克隆抗体
种类完整抗体
目标葡萄球菌脂磷壁酸
临床资料
ATC码
  • 未分配
识别信息
CAS号595566-61-3  checkY
ChemSpider
UNII
化学信息
化学式C6462H9996N1728O2028S54
摩尔质量146,072.36 g·mol−1

参考资料

编辑
  1. ^ Weisman LE, Thackray HM, Garcia-Prats JA, Nesin M, Schneider JH, Fretz J, et al. Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates. Antimicrobial Agents and Chemotherapy. July 2009, 53 (7): 2879–86. PMC 2704668 . PMID 19380597. doi:10.1128/AAC.01565-08. 
  2. ^ Clinical trial number NCT00646399 for "Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis" at ClinicalTrials.gov